Skip to main content
Premium Trial:

Request an Annual Quote

UC, San Diego Selected as Site for Benitec HCV Drug Trial

Premium

Benitec Biopharma this week announced that the University of California, San Diego, has been selected as another site of the company’s phase I/II trial of the expressed RNAi-based hepatitis C treatment TT-034.

Last month, the company said that the Duke Clinical Research Unit would also be a site for the trial (GSN 3/28/2013).

The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.

It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.